Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

AZ, Amgen’s SOURCE trial misses primary endpoint

AstraZeneca and Amgen have announced that a phase III trial of their new medicine tezepelumab failed to meet the primary endpoint in patients with severe, oral corticosteroid-dependent asthma.

The SOURCE trial failed to meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroids dose, without loss of asthma control, with tezepelumab compared to placebo.

However, the drug’s effect on other measures of efficacy was similar to those observed in previous trials, AZ said in a statement.

“Based on the totality of evidence, including the compelling exacerbation reduction results seen in the registrational NAVIGATOR phase III trial and the PATHWAY phase IIb trial, we remain confident that tezepelumab has the potential to improve care for a broad population of severe asthma patients,” said Mene Pangalos, executive vice president, BioPharmaceuticals R&D.

“Our initial analysis of SOURCE in oral corticosteroid-dependent asthma indicates that the trial design may have contributed to the result of the primary endpoint. We are in the process of further analysing the data from SOURCE and look forward to sharing these results with the medical community,” he added.

Tezepelumab is a monoclonal antibody designed to inhibit the action of thymic stromal lymphopoietin, a key epithelial cytokine which is critical in the initiation and persistence of allergic, eosinophilic and other types of airway inflammation associated with severe asthma.

In November, AZ and Amgen announced positive results from the NAVIGATOR phase III trial, which met the primary endpoint and demonstrated a statistically significant reduction in the annualised asthma exacerbation rate.

22nd December 2020

http://www.pharmatimes.com/

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies